Transparency notification Wellington

Brussels (Belgium), 19 October 2026 – 22:00 (CET) – Regulated information 

1.  Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from Wellington Management Group LLP (having its registered offices at 280 Congress Street, Boston, MA 02210, USA) on 15 October 2026. 

Wellington Management Group LLP has notified that, following a disposal of UCB voting securities or voting rights by its affiliates, its shareholding in UCB SA/NV has decreased and it has crossed the 3% threshold downwards, on 14 October 2026.

On 14 October 2026, Wellington Management Group LLP (taking into account the holdings of its affiliates) owned less than 3% of UCB shares with voting rights or equivalent financial instruments of the total number of shares issued by the company (194 505 658), versus 3.01% (5 846 454 voting rights) in the previous notification dated 26 August 2026.

2.  Content of the notification

• Reason for the notification: Acquisition or disposal of voting securities or voting rights; downward crossing of the lowest threshold. 
• Notification by: A parent undertaking or a controlling person.
• Persons subject to the notification requirement: 

• Date on which the threshold is crossed: 14 October 2026. 
• Threshold crossed (in %): 3%.
• Denominator: 194 505 658.
• Notified details:

• Chain of controlled undertakings through which the holding is effectively held:

Wellington Management Company LLP is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Management Group LLP. Wellington Management Hong Kong Ltd, Wellington Management International Ltd and Wellington Management Europe GmbH are direct controlled undertakings of Wellington Management Global Holdings, Ltd. which, in turn, is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.  The shares are registered in the names of the Accounts or nominees according to their respective holdings.

• Additional information: Wellington Management Company LLP, Wellington Management Hong Kong Ltd, Wellington Management International Ltd and Wellington Management Europe GmbH are investment management companies and can exercise the voting rights at their discretion in the absence of specific instructions from the beneficial owners of the shares.

3.  Further information 

This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

For further information, contact UCB: 

Investor Relations

Yvonne Naughton

T: +44.175.344.7521  

Yvonne.Naughton@ucb.com

Sahar Yazdian

T: +32.2.559.9137

sahar.yazdian@ucb.com

Corporate Communications

Laurent Schots 

T+32 2 559 92 64

laurent.schots@ucb.com     

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB).